|
|
Exosomal Drug Delivery
|
1R44CA221487-01
|
$719,680
|
$719,680
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
$1,154,726
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
1R43CA217502-01A1
|
$300,000
|
$99,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$364,614
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-18
|
$417,500
|
$137,775
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
$16,185
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The Metastatic Cascade: Macrophages Lead the Way
|
5R01CA172451-06
|
$439,400
|
$145,002
|
POLLARD, JEFFREY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
RCT of An Internet Cessation Program Plus Online Social Network for HIV + Smokers
|
5R01CA192954-04
|
$634,880
|
$634,880
|
SHUTER, JONATHAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Methylome characterization of bronchial epithelial projenitor cells
|
1R21CA209436-01A1
|
$216,172
|
$216,172
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Develop and Apply a Novel Genome-wide Mendelian Randomization Method to Examine Relationship between Obesity and Lung Cancer
|
5R21CA202529-02
|
$208,405
|
$208,405
|
WANG, TAO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
AMERICAN S FOR NONSMOKERS RIGHTS SMOKEFREE ORDINANCES DATA -- CATALOG # : 1
|
261201700689P
|
$16,550
|
$16,550
|
UNKNOWN, UNKNOWN
|
AMERICAN NONSMOKERS RIGH
|
|
|
Practical high resolution microscopy of un-cut, un-embedded lung biopsies
|
2R44CA189522-02
|
$1,091,279
|
$1,091,279
|
LEVENE, MICHAEL
|
APPLIKATE TECHNOLOGIES, LLC
|
|
|
Novel approaches to study immune responses to post translational modifications for cancer detection
|
5U01CA214201-02
|
$462,286
|
$231,143
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
A Psychosocial Intervention for the Caregivers of Advanced Lung Cancer Patients
|
5R01CA187143-04
|
$456,456
|
$456,456
|
BADR, HODA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
ALK causes TGF-beta insensitivity in lung cancer cells
|
5R21CA209007-02
|
$206,843
|
$206,843
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Lung Cancer Prediction Models Incorporating Exome Data from Extreme Phenotypes
|
5K07CA181480-04
|
$127,883
|
$127,883
|
LIU, YANHONG
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Integration of Palliative Care for Cancer Patients on Phase I Trials
|
5R01CA177562-04
|
$1,356,827
|
$1,356,827
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
$4,398
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
$7,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
$146,801
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
A Quantitative Epigenetic Test for Guiding Smoking Cessation Therapy
|
5R44CA213507-02
|
$642,098
|
$642,098
|
PHILIBERT, ROBERT
|
BEHAVIORAL DIAGNOSTICS, INC.
|
|
|
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg Effect
|
5R01CA169470-05
|
$361,050
|
$361,050
|
GRANT, AARON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A multi-faceted approach to identifying K-Ras synthetic lethal relationships
|
5U01CA199252-03
|
$1,041,188
|
$520,594
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Overcoming resistance to tyrosine kinase inhibitors in lung cancer
|
5R01CA169259-05
|
$1
|
$1
|
KOBAYASHI, SUSUMU
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.
|
4R44CA203068-02
|
$988,207
|
$988,207
|
BERTENSHAW, GREG
|
BIOMARKER STRATEGIES, LLC
|
|
|
CORE ACTIVITIES; BASE PERIOD 09/01/17-04/30/18. CAN 8481401. $1,200,000
|
261201700004I
|
$1,200,000
|
$1,200,000
|
UNKNOWN, UNKNOWN
|
BIZZELL GROUP LLC, THE
|
|
|
Role of Insulin Receptor Substrates in Kras-driven lung cancer
|
1R01CA211944-01A1
|
$404,888
|
$404,888
|
KALAANY, NADA
|
BOSTON CHILDREN'S HOSPITAL
|
|
|
Modeling bi-directional signaling and cytoskeletal dynamics in 3D cell migrations
|
5U01CA177799-05
|
$571,427
|
$285,714
|
ZAMAN, MUHAMMAD
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
2U01CA164974-07
|
$2,195,369
|
$439,074
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5UM1CA164974-06
|
$639,740
|
$127,948
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Molecular and Imaging Biomarkers for Early Lung Cancer Detection in the Setting of Indeterminate Pulmonary Nodules
|
5R01CA210360-02
|
$627,525
|
$627,525
|
SPIRA, AVRUM
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
The Boston University-UCLA Lung Cancer Biomarker Development Lab
|
5U01CA214182-02
|
$860,456
|
$860,456
|
SPIRA, AVRUM
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-04S1
|
$2,088,480
|
$208,848
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-04
|
$11,145,123
|
$1,114,512
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatment
|
1R01CA203636-01A1
|
$606,587
|
$606,587
|
NISHINO, MIZUKI
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Systemic RNA Delivery to Tumors
|
5R01CA200900-02
|
$547,422
|
$547,422
|
SHI, JINJUN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Center of Excellence for High Throughput Proteogenomic Characterization
|
5U24CA210986-02
|
$1,288,045
|
$425,055
|
CARR, STEVEN
|
BROAD INSTITUTE, INC.
|
|
|
Systematic identification of oncogenic KRAS synthetic lethal interactions
|
5U01CA199253-03
|
$807,776
|
$266,566
|
HAHN, WILLIAM
|
BROAD INSTITUTE, INC.
|
|
|
Outcomes associated with significant incidental findings in lung cancer screening
|
1R01CA204222-01A1
|
$345,401
|
$345,401
|
GAREEN, ILANA
|
BROWN UNIVERSITY
|
|
|
Positive Psychotherapy for Smoking Cessation Enhanced with Text Messaging: A Randomized Controlled Trial
|
5R01CA201262-02
|
$564,403
|
$564,403
|
KAHLER, CHRISTOPHER
|
BROWN UNIVERSITY
|
|
|
Aerobic Exercise for Smokers with Depressive Symptomatology
|
5R01CA173551-05
|
$509,755
|
$509,755
|
ABRANTES, ANA
|
BUTLER HOSPITAL (PROVIDENCE, RI)
|
|
|
Lung cancer in never smokers: incidence, risk factors, and molecular characteristics in Asian American, Native Hawaiian and Pacific Islander females
|
5R01CA204070-02
|
$572,056
|
$572,056
|
GOMEZ, SCARLETT
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
3U10CA180853-04S1
|
$76,498
|
$5,737
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-04
|
$1,188,450
|
$89,134
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Caveolae-Targeted Cisplatin Immunoconjugates for Effective Lung Cancer Therapy
|
1R41CA217399-01A1
|
$299,999
|
$299,999
|
LEVIN, MICHAEL
|
CAVATAR, LLC
|
|
|
SUPPORT OF THE TUS-CPS SMALL AREA ESTIMATION PROJECT
|
APC16013
|
$15,000
|
$15,000
|
UNKNOWN, UNKNOWN
|
CENSUS, UNITED STATES BUREAU OF THE
|
|
|
CENSUS IAA: TUS-CPS
|
APC17010
|
$740,000
|
$740,000
|
UNKNOWN, UNKNOWN
|
CENSUS, UNITED STATES BUREAU OF THE
|
|
|
FOR EDRG WITH CDC/NDI. IT IS FOR NATIONAL DEATH INDEX DATA- NLST & PLCO. 07/20/2017-07/19/2018
|
ACN17006
|
$113,818
|
$28,455
|
UNKNOWN, UNKNOWN
|
CENTERS FOR DISEASE CONTROL & PREVENTION
|
|
|
CDC: COMMUNITY GUIDE IMPLEMENTATION
|
APC17008
|
$75,000
|
$75,000
|
UNKNOWN, UNKNOWN
|
CENTERS FOR DISEASE CONTROL & PREVENTION
|
|
Total relevant funding to Lung for this search: $311,733,048
|
